CDH19 and cancer: Due to the expression changes of CDH19 and the influence of sorafenib on the histone modification profiling at its promoter during EMT, we hypothesize that CDH19 could act as another vital mediator of EMT and a novel therapeutic target for the treatment of organ fibrosis and cancer.